Basic Instinct: The Insulin Profit Machine

September 22, 2022
You must provide your professional email address to view this content.

On the surface, insulin manufacturers have a lot of attractive characteristics for investors; a product unaffected by the economic cycle, increasing demand from more obesity, price inelasticity and very high profit margins. However, when we examine their situation in greater detail, risks emerge: regulatory risks from the unenviable global position of the U.S for relative health care costs and egregious behavior is resulting in compelling public campaigns against insulin manufacturers. Moreover, investors may start to divest from companies with bad behavior delivering unsocially sustainable levels of profit.

Disclaimer / Securities Disclosure

SECURITIES DISCLOSURE
The author(s) of this research note do (does) not personally hold a any position in any of the above-mentioned securities.
Nordis Capital (SMS’ sister company) does hold a position NOVO.B DC in its ESG funds.

DISCLAIMER
© Sustainable Market Strategies, a division of SMS Financial Technologies inc. Redistribution prohibited without prior consent. This report has been prepared by Sustainable Market Strategies mainly for distribution to market professionals and institutional investors. It should not be considered as investment advice or a recommendation to purchase any particular security, strategy, or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.